Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth

Carcinogenesis

Volumn 33, Issue 11, 2012, Pages 2283-2292

  Rico, Charlène ^a   Laguë, Marie Noëlle ^a   Lefévre, Pavine ^b   Tsoi, Mayra ^a   Dodelet devillers, Aurore ^a   Kumar, Vikas ^a   Lapointe, Evelyne ^a   Paquet, Marilène ^c   Nadeau, Marie Éve ^a   Boerboom, Derek ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; INITIATION FACTOR 4B; MAMMALIAN TARGET OF RAPAMYCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; S6 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; ENZYME PHOSPHORYLATION; FEMALE; GRANULOSA CELL TUMOR; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANIMALS; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CELL PROLIFERATION; EUKARYOTIC INITIATION FACTORS; FEMALE; GRANULOSA CELL TUMOR; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, TRANSGENIC; PERITONEAL NEOPLASMS; PHOSPHORYLATION; PTEN PHOSPHOHYDROLASE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIROLIMUS; SURVIVAL RATE; TOR SERINE-THREONINE KINASES;

EID: 84868618179     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs263     Document Type: Article

References (61)

1. Schumer, S.T. et al. (2003) Granulosa cell tumor of the ovary. J. Clin. Oncol., 21, 1180-1189.
2. Jubb, K.V.F. (1993) Pathology of Domestic Animals. American Press, San Diego, CA.
3. Amsterdam, A. et al. (1997) Control of differentiation, transformation, and apoptosis in granulosa cells by oncogenes, oncoviruses, and tumor suppressor genes. Endocr. Rev., 18, 435-461.
4. East, N. et al. (2005) Granulosa cell tumour: a recurrence 40 years after initial diagnosis. J. Obstet. Gynaecol. Can., 27, 363-364.
5. Villella, J. et al. (2007) Clinical and pathological predictive factors in women with adult-type granulosa cell tumor of the ovary. Int. J. Gynecol. Pathol., 26, 154-159.
6. Jamieson, S. et al. (2012) Molecular pathogenesis of granulosa cell tumors of the ovary. Endocr. Rev., 33, 109-144.
7. Alexiadis, M. et al. (2011) Nuclear receptor profiling of ovarian granulosa cell tumors. Horm. Cancer, 2, 157-169.
8. Gershon, R. et al. (2011) FOXL2 C402G mutation detection using MALDI-TOF-MS in DNA extracted from Israeli granulosa cell tumors. Gynecol. Oncol., 122, 580-584.
9. Kim, J.H. et al. (2011) Differential apoptotic activities of wild-type FOXL2 and the adult-type granulosa cell tumor-associated mutant FOXL2 (C134W). Oncogene, 30, 1653-1663.
10. Kim, M.S. et al. (2010) Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers. J. Pathol., 221, 147-152.
11. Shah, S.P. et al. (2009) Mutation of FOXL2 in granulosa-cell tumors of the ovary. N. Engl. J. Med., 360, 2719-2729.
12. Kotlar, T.J. et al. (1997) A mutation in the follicle-stimulating hormone receptor occurs frequently in human ovarian sex cord tumors. J. Clin. Endocrinol. Metab., 82, 1020-1026.
13. Fuller, P.J. et al. (1998) No evidence of a role for mutations or polymorphisms of the follicle-stimulating hormone receptor in ovarian granulosa cell tumors. J. Clin. Endocrinol. Metab., 83, 274-279.
14. Giacaglia, L.R. et al. (2000) No evidence of somatic activating mutations on gonadotropin receptor genes in sex cord stromal tumors. Fertil. Steril., 74, 992-995.
15. Hussein, S. et al. (1999) Comment on analysis of mutations in genes of the follicle-stimulating hormone receptor in ovarian granulosa cell tumors. J. Clin. Endocrinol. Metab., 84, 3852.
16. Fragoso, M.C. et al. (1998) Activating mutation of the stimulatory G protein (gsp) as a putative cause of ovarian and testicular human stromal Leydig cell tumors. J. Clin. Endocrinol. Metab., 83, 2074-2078.
17. Ligtenberg, M.J. et al. (1999) Analysis of mutations in genes of the folliclestimulating hormone receptor signaling pathway in ovarian granulosa cell tumors. J. Clin. Endocrinol. Metab., 84, 2233-2234.
18. Shen, Y. et al. (1996) Absence of the previously reported G protein oncogene (gip2) in ovarian granulosa cell tumors. J. Clin. Endocrinol. Metab., 81, 4159-4161.
19. Richards, J.S. (1994) Hormonal control of gene expression in the ovary. Endocr. Rev., 15, 725-751.
20. Hunzicker-Dunn, M. et al. (2006) FSH signaling pathways in immature granulosa cells that regulate target gene expression: branching out from protein kinase A. Cell. Signal., 18, 1351-1359.
21. Ongeri, E.M. et al. (2005) Follicle-stimulating hormone induction of ovarian insulin-like growth factor-binding protein-3 transcription requires a TATA box-binding protein and the protein kinase A and phosphatidylinositol-3 kinase pathways. Mol. Endocrinol., 19, 1837-1848.
22. Wayne, C.M. et al. (2007) Follicle-stimulating hormone induces multiple signaling cascades: evidence that activation of Rous sarcoma oncogene, RAS, and the epidermal growth factor receptor are critical for granulosa cell differentiation. Mol. Endocrinol., 21, 1940-1957.
23. Bittinger, S. et al. (2009) Expression status and mutational analysis of the PTEN and P13K subunit genes in ovarian granulosa cell tumors. Int. J. Gynecol. Cancer, 19, 339-342.
24. Alam, H. et al. (2004) Follicle-stimulating hormone activation of hypoxiainducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation. J. Biol. Chem., 279, 19431-19440.
25. Hirashima, K. et al. (2010) Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma. Br. J. Cancer., 106, 876-882.
26. Hou, G. et al. (2010) mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice. Cancer Lett., 290, 248-254.
27. Herberger, B. et al. (2007) Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin. Cancer Res., 13, 4795-4799.
28. Hudes, G.R. (2009) Targeting mTOR in renal cell carcinoma. Cancer, 115, 2313-2320.
29. Laguë, M.N. et al. (2008) Synergistic effects of Pten loss and WNT/ CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression. Carcinogenesis, 29, 2062-2072.
30. Boerboom, D. et al. (2005) Misregulated Wnt/beta-catenin signaling leads to ovarian granulosa cell tumor development. Cancer Res., 65, 9206-9215.
31. Groszer, M. et al. (2001) Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science, 294, 2186-2189.
32. Harada, N. et al. (1999) Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J., 18, 5931-5942.
33. Jamin, S.P. et al. (2002) Requirement of Bmpr1a for Müllerian duct regression during male sexual development. Nat. Genet., 32, 408-410.
34. Jorgez, C.J. et al. (2004) Granulosa cell-specific inactivation of follistatin causes female fertility defects. Mol. Endocrinol., 18, 953-967.
35. Nadeau, M.E. et al. (2009) A mouse surgical model for metastatic ovarian granulosa cell tumor. Comp. Med., 59, 553-556.
36. Zeleznik, A.J. et al. (1974) Granulosa cell maturation in the rat: increased binding of human chorionic gonadotropin following treatment with follicle-stimulating hormone in vivo. Endocrinology, 95, 818-825.
37. Pectasides, D. et al. (2007) Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat. Rev., 33, 177-190.
38. Chiang, G.G. et al. (2005) Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J. Biol. Chem., 280, 25485-25490.
39. Magnuson, B. et al. (2012) Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem. J., 441, 1-21.
40. Iadevaia, V. et al. (2012) Roles of the mammalian target of rapamycin, mTOR, in controlling ribosome biogenesis and protein synthesis. Biochem. Soc. Trans., 40, 168-172.
41. Iadevaia, V. et al. (2012) Evaluation of mTOR-regulated mRNA translation. Methods Mol. Biol., 821, 171-185.
42. Wouters, B.G. et al. (2008) Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer, 8, 851-864.
43. Kim, J.E. et al. (2004) regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes, 53, 2748-2756.
44. Kapoor, A. (2009) Inhibition of mTOR in kidney cancer. Curr. Oncol., 16 Suppl 1, S33-S39.
45. Scott, K.L. et al. (2009) GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature, 459, 1085-1090.
46. Mabuchi, S. et al. (2007) RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res., 67, 2408-2413.
47. Mabuchi, S. et al. (2009) mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin. Cancer Res., 15, 5404-5413.
48. Behbakht, K. et al. (2011) Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol. Oncol., 123, 19-26.
49. Espeillac, C. et al. (2011) S6 kinase 1 is required for rapamycin-sensitive liver proliferation after mouse hepatectomy. J. Clin. Invest., 121, 2821-2832.
50. Fingar, D.C. et al. (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol., 24, 200-216.
51. Deng, H. et al. (2010) p70 Ribosomal S6 kinase is required for airway smooth muscle cell size enlargement but not increased contractile protein expression. Am. J. Respir. Cell Mol. Biol., 42, 744-752.
52. Fingar, D.C. et al. (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev., 16, 1472-1487.
53. Ohanna, M. et al. (2005) Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat. Cell Biol., 7, 286-294.
54. Shahbazian, D. et al. (2010) eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways. Cell Cycle, 9, 4106-4109.
55. Chen, S.M. et al. (2012) Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR. Biochem. Pharmacol., 83, 1183-1194.
56. De Luca, A. et al. (2012) The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin. Ther. Targets, 16 Suppl 2, S17-S27.
57. Altman, J.K. et al. (2011) Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin. Cancer Res., 17, 4378-4388.
58. Falcon, B.L. et al. (2011) Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/ mTORC2 inhibitors. Cancer Res., 71, 1573-1583.
59. Gulhati, P. et al. (2011) mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res., 71, 3246-3256.
60. Gupta, M. et al. (2012) Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood, 119, 476-487.
61. Tanwar, P.S. et al. (2011) Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/β-catenin and PTEN. PLoS ONE, 6, e20715.